Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
04:35pm, Tuesday, 25'th Mar 2025
INDIANAPOLIS , March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented a
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
12:59pm, Tuesday, 25'th Mar 2025
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
11:25am, Tuesday, 25'th Mar 2025
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment
Eli Lilly Shares Rise Over 2% After Key Signal
05:13pm, Monday, 24'th Mar 2025
LLY CLIMBS OVER 17 POINTS AT ITS HIGH
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
01:29pm, Monday, 24'th Mar 2025
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
09:45am, Monday, 24'th Mar 2025
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars?
09:31am, Monday, 24'th Mar 2025
Eli Lilly and Co (NYSE:LLY) is tightening its grip on the obesity drug market, with its injectable treatment Zepbound gaining momentum over Novo Nordisk's Wegovy, according to Berenberg. The investmen
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound
08:31am, Monday, 24'th Mar 2025
New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vials New integration means streamline
Market Sell-Off: Can Buying These 3 "Safe" Stocks Today Set You Up for Life?
08:00am, Monday, 24'th Mar 2025
The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment and strong uptake of artificial intelligence technologies. The benchmark S&P
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
04:43am, Sunday, 23'rd Mar 2025
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and accor
Eli Lilly: Growth With Higher Margins
09:38am, Friday, 21'st Mar 2025
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash f
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
12:06pm, Thursday, 20'th Mar 2025
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
05:25am, Thursday, 20'th Mar 2025
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
02:54am, Thursday, 20'th Mar 2025
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Eli Lilly: A Safe Harbor Amid Market Volatility
02:58pm, Monday, 17'th Mar 2025
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and st
